FIELD: biochemistry.
SUBSTANCE: invention relates to the use of a compound represented by formula II, enantiomers thereof, diastereoisomers or pharmaceutically acceptable salts in the treatment of a disorder associated with the modulation of the N-formylpeptide receptor 1 (FPRL-1). In formula II, a is equal to 1 and b is equal to 0; a is equal to 0 and b is equal to 1; a is equal to 1 and b is equal to 1; R1 is a C1-8 alkyl, not necessarily substituted by hydroxyl, -NR11R12 or -OR13; R2 is a C1-8 alkyl, not necessarily substituted by C6-10 aryl, amide or heterocycle, the heterocycle is in the form of a 3-10-member aromatic ring containing at least one heteroatom selected from N; one methyl alkyl group can be replaced by sulphur or sulfonyl; R3 is in the form of hydrogen or halogen; R4 is in the form of hydrogen; R5 is a halogen, either -CF3 or -S(O)nR14; n is 0, 1 or 2; R6 is hydrogen; R7 is hydrogen or halogen; R8 is hydrogen or C1-8 alkyl; R9 is hydrogen, C1-8 alkyl, not necessarily substituted for hydroxyl, or C6-10 aryl; R10 is hydrogen, C1-8 alkyl, not necessarily substituted by hydroxyl, or C6-10 aryl; R9a is hydrogen or C1-8 alkyl, not necessarily substituted by hydroxyl; R10a is hydrogen or C1-8 alkyl, not necessarily substituted by hydroxyl; R11 is hydrogen or C1-8 alkyl; R12 is hydrogen or C1-8 alkyl; R13 is hydrogen or C1-8 alkyl; R14 is CF3 or C1-8 alkyl. Furthermore, the disorder associated with the modulation of the N-formylpeptide receptor 1 is selected from a group consisting of inflammatory eye diseases, including, but not limited to, uveitis, dryness of the eye, keratitis, allergic eye disease, infectious keratitis, herpetic keratitis, corneal angiogenesis, lyfangiogenesis, retinitis, chorioiditis, acute multifocal placoid pigment epithelial disease, Behçet's disease, postoperative retinal healing, wet and dry age-related macular degeneration (ARMD); systemic inflammatory diseases; pain; immunological disorders; healing of skin wounds; burns; pink acne; atopic dermatitis; acne; psoriasis; seborrhea dermatitis; actic keratosis; common warts; photoaging; rheumatoid arthritis and related inflammatory disorders.
EFFECT: invention enables effective treatment of a disorder associated with the modulation of the N-formylpeptide receptor 1 (FPRL-1).
Formula II
39 cl, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMID DERIVATIVES OF N-CARBAMIDE-SUBSTITUTED AMINO ACIDS AS MODULATORS OF FORMYLPEPTIDE RECEPTOR-1 (FPRL-1) | 2012 |
|
RU2629205C2 |
| USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING INFLAMMATORY EYE DISEASES | 2014 |
|
RU2663911C2 |
| PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | 2014 |
|
RU2703725C1 |
| DERIVATIVES OF N-UREA-SUBSTITUTED AMINOACIDS AS MODULATORS OF FORMYL-PEPTIDE RECEPTOR | 2014 |
|
RU2696581C2 |
| USE OF FORMYL PEPTIDE RECEPTOR 2 AGONISTS FOR TREATING INFLAMMATORY EYE DISEASES | 2014 |
|
RU2768730C2 |
| USING FORMYLPEPTIDE RECEPTOR 2 AGONISTS FOR TREATING DERMATOLOGIC DISEASES | 2014 |
|
RU2696487C2 |
| DERIVATIVES OF 2,5-DIOXOIMIDAZOLIDINE-1-YL-3-PHENYLUREA AS MODULATORS OF FORMYLPEEPTITIDE RECEPTOR 1 (FPRL-1) | 2012 |
|
RU2645673C2 |
| ARYL UREA DERIVATIVES AS N-FORMILEPEPTIDE-1 RECEPTOR (FPRL-1) MODULATORS | 2012 |
|
RU2627271C2 |
| PRODRUG 1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | 2003 |
|
RU2357962C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
